Endnu en undersøgelse vedrørte Invegas evne til på lang sigt at forhindre nye symptomer i indtil 35 uger hos 207 patienter, der i forvejen var blevet behandlet for symptomer på skizofreni i en 14 ugers periode.
A further study looked at the long-term effects of Invega in preventing new symptoms for up to 35 weeks in 207 patients who had initially been treated for symptoms of schizophrenia over a 14-week period.